Influence of vitamin K deficiency on response to novel anticoagulants
Research type
Research Study
Full title
Investigation of the effect of vitamin K deficiency upon anticoagulant response to novel oral anticoagulants (direct thrombin inhibitors and FXa inhibitors) ex-vivo
IRAS ID
208502
Contact name
Farhad Kamali
Contact email
Sponsor organisation
Newcastle upon Tyne Hosptials NHS Foundation Trust
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
Anticoagulation with warfarin has long been established for treatment and prevention of clotting disorders. Its action is exagerated by vitamin K deficiency. Novel oral anticoagulants have been licensed and are available for use according to their licensed indications. Whilst clinical trials suggest that the novel oral anticoagulants are safe, the impact of dietary vitamin K status on anticoagulation response has not been studied. There is evidence that vitamin K deficiency in rats enhances anticoagulant response to the direct thrombin inhibitor Ximelagatran. We have investigated the possible effect of dietary vitamin K deficiency on anticoagulation response in man by comparing response of clotting factors to the factor Xa inhibitor, rivaroxaban, in the laboratory ex-vivo using blood samples obtained from people with a normal or deficient vitamin K diet, and noted anticoagulant response to be exaggerated in vitamin K deficient older people compared with younger people replete in vitamin K. We wish to assess whether this observation is also the case for the other factor Xa inhibitors apixaban and edoxaban, and for the direct thrombin inhibitor dabigatran.
REC name
West of Scotland REC 5
REC reference
16/WS/0184
Date of REC Opinion
11 Oct 2016
REC opinion
Further Information Favourable Opinion